查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830991

骨质疏鬆症治疗市场

Osteoporosis Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计骨质疏鬆症治疗市场将从 2024 年的 171.7 亿美元成长到 2031 年的 227.2 亿美元，2025 年至 2031 年的复合年增长率为 3.8%。

分析师观点：本报告概述了当前骨质疏鬆症治疗市场趋势所驱动的成长机会及其在预测期内的预期影响。骨质疏鬆症会导致骨骼脆弱，即使是轻微的跌倒也可能导致骨折，严重影响生活品质。早期发现和治疗可以减缓或阻止骨质疏鬆症的进展，从而降低骨折风险。因此，骨质疏鬆症盛行率的上升增加了对诊断的需求，这反过来又推动了骨质疏鬆症治疗市场的成长。由于更年期荷尔蒙变化会影响骨密度，这种疾病主要见于女性。其他导致老年人骨质疏鬆症风险的因素包括类风湿性关节炎、家族病史、长期使用骨质疏鬆药物。根据国际骨质疏鬆症基金会的数据，在骨质疏鬆症患者中，25% 为女性，5% 为 65 岁以上的男性。

市场概览：骨质疏鬆症是一种进展性疾病，对男性、停经后女性和老年人而言，骨折风险较高。骨质疏鬆症患者尤其容易发生骨骼、髋部、前臂、脊椎和腕部骨折。它被归类为一种代谢紊乱，会降低骨密度，从而导致骨折。治疗方案通常包括双磷酸盐、荷尔蒙疗法、地诺单抗和各种营养补充剂，以及生活方式的改变，例如增加体力活动和富含钙的饮食。推动骨质疏鬆症治疗市场成长的关键因素包括医疗保健在研究和药物开发方面的支出不断增加，以及人们对现有骨质疏鬆症治疗方法的认识不断提高。

策略洞察市场驱动力：骨质疏鬆症发病率上升和生活方式改变推动市场扩张。全球骨质疏鬆症的盛行率正在上升，主要原因是不健康的生活方式、营养不良、运动不足、钙和维生素D摄取量低以及荷尔蒙失衡。国际骨质疏鬆症基金会报告称，骨质疏鬆症每年导致超过890万人骨折，相当于每三秒钟就会发生一起骨质疏鬆性骨折，全球约有2亿名女性受到影响。老年人口的增加是推动骨质疏鬆症治疗市场成长的另一个重要因素。 Labiotech发表的一项名为《骨质疏鬆症研究进展》的研究表明，约有1000万美国人患有骨质疏鬆症，其中约4400万人骨密度低，这增加了他们患骨质疏鬆症的风险。骨质疏鬆症的可能性随着年龄的增长而增加；50岁及以上的成年人骨折风险较高。在美国，65岁及以上髋部骨折患者中四分之三为女性，其中约15%至36%的患者会在一年内死亡。人们对整体健康和保健的日益关注推动了定期健康筛检，包括骨密度评估。随着人们越来越关注自身的骨骼健康，早期诊断和介入变得至关重要，这进一步推动了市场成长。人们对骨骼健康的认识不断提高，对预防和治疗解决方案的需求也随之增加，这大大促进了骨质疏鬆症治疗市场的发展。

节段分析：

透过检查以下部分对骨质疏鬆症治疗市场进行分析：药物类别、类型、给药途径和配销通路。

就药物类别而言，骨质疏鬆症治疗市场分为RANKL抑制剂、双磷酸盐类药物、选择性雌激素受体调节剂 (SERM)、荷尔蒙疗法等。 RANKL类药物在2023年占据了最大的市场份额，而荷尔蒙疗法类药物预计在2023年至2031年期间的复合年增长率最高。双磷酸盐类药物在骨质疏鬆症治疗市场中也占有相当大的份额。双磷酸盐类药物，包括阿崙膦酸盐和唑来膦酸，可有效抑制骨吸收、增强骨密度并降低骨折风险。其丰富的临床应用、监管部门的批准以及口服和静脉注射两种剂型的可用性，使其成为医疗保健提供者的首选。此外，其成本效益和广泛的保险覆盖范围也使其在骨质疏鬆症治疗中广泛使用。

市场依类型分为原发性骨质疏鬆症及继发性骨质疏鬆症。 2023年，原发性骨质疏鬆症在骨质疏鬆症治疗市场中占有较大份额。原发性骨质疏鬆症与老化有关，导致骨骼更新逐渐下降。美国国家医学图书馆发表的一项题为《停经后女性原发性骨质疏鬆症和低骨量患病率及相关风险因素》的研究表明，全球30%的50岁以上女性患有骨质疏鬆症，每年8%至9%的骨折归因于此。此外，70岁及以上的男性和女性会经历骨骼形成和流失之间的不平衡，导致背痛、生活品质下降和日常活动困难。

就给药途径而言，骨质疏鬆症治疗市场分为口服和注射两种形式。注射剂在2023年占据了最大的市场份额，预计在2023年至2031年期间将实现最高的复合年增长率。注射剂的主导地位可归因于其作为给药方式的有效性和可靠性。透过注射给药可使药物直接进入血液，确保快速且可预测的吸收，这对骨质疏鬆症治疗至关重要。此外，一些骨质疏鬆症药物仅以注射剂形式提供，进一步提升了该领域的市场份额。随着患者对自行注射的依从性的提高以及给药技术的不断进步，注射剂领域已做好准备，保持其强劲的市场份额。

区域分析：骨质疏鬆症治疗市场报告涵盖北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美市场在 2023 年的价值为 82.6 亿美元，预计到 2031 年将达到 112.6 亿美元，2023 年至 2031 年期间的预期复合年增长率为 3.9%。推动该地区市场成长的一个重要因素是人口老化严重，加上人们对骨质疏鬆症的认识不断提高。此外，先进的医疗基础设施和全面的医疗服务有助于及时诊断和治疗。大型製药公司的存在和持续的研发努力也促进了创新疗法的引入。此外，优惠的报销政策和保险覆盖为寻求骨质疏鬆症治疗的患者提供支持，从而促进北美市场的成长。

亚太地区骨质疏鬆症治疗市场预计将达到4.7%的最高复合年增长率。该地区，尤其是印度和中国等国家，拥有庞大的製药产业，而中国是製造业中心。该地区的预期成长主要得益于蓬勃发展的中产阶级和医疗服务可近性的改善。此外，医疗基础设施的进步和新兴製药产业的蓬勃发展，使亚太地区成为骨质疏鬆症治疗市场实现显着成长和发展的关键地区。

骨质疏鬆症治疗市场报告范围关键参与者分析：骨质疏鬆症治疗市场报告中介绍的关键参与者包括辉瑞公司、安进公司、卡迪拉製药、礼来公司、第一三共株式会社、梯瓦製药公司、旭化成株式会社、诺华公司、中外製药公司有限公司。

最新动态：

骨质疏鬆症治疗市场中的公司正将併购作为主要的成长策略。市场近期的发展包括：

2021年10月，知名生技公司Entera Bio宣布其中期口服骨质疏鬆症药物製剂研究的重要资料，进入3期註册阶段。 2021年8月，印度药品管理总局（DCGI）向Enzene Biosciences Ltd授予其生物相似药Denosumab的上市许可（MA），用于治疗成人骨质疏鬆症。 2021年1月，总部位于伦敦的製药公司Theramex在欧洲推出了骨质疏鬆症药物Livogiva。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：骨质疏鬆症治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：骨质疏鬆症治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：骨质疏鬆症治疗市场－全球市场分析

  • 骨质疏鬆症治疗 - 全球市场概览
  • 骨质疏鬆症治疗－全球市场及2031年预测

第七章：骨质疏鬆症治疗市场-收入分析-依药物类型，2021-2031

  • 概述
  • RANKL 抑制剂
  • 双磷酸盐
  • 荷尔蒙
  • 选择性雌激素受体调节剂（SERM）
  • 其他的

第 8 章：骨质疏鬆症治疗市场 - 收入分析 - 依给药途径，2021-2031 年

  • 概述
  • 口服
  • 注射剂

第九章：骨质疏鬆症治疗市场-收入分析-按类型，2021-2031

  • 概述
  • 原发性骨质疏鬆症
  • 继发性骨质疏鬆症

第 10 章：骨质疏鬆症治疗市场 - 收入分析 - 按配销通路，2021-2031 年

  • 概述
  • 医院
  • 零售药局
  • 网路药局

第 11 章：骨质疏鬆症治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 13 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 14 章：骨质疏鬆症治疗市场 - 主要公司简介

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Amgen Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Chugai Pharmaceuticals Co. Ltd.
  • Teijin Pharma Limited
  • Novartis AG
  • Eli Lily and Company
  • Asahi Kasei Pharma Corporation

第 15 章：附录

简介目录
Product Code: TIPRE00004071

The osteoporosis treatment market is anticipated to grow from US$ 17.17 billion in 2024 to US$ 22.72 billion by 2031, reflecting a projected CAGR of 3.8% from 2025 to 2031.

Analyst Perspective:This report outlines growth opportunities driven by current trends in the osteoporosis treatment market and their expected effects during the forecast period. Osteoporosis can lead to fragile bones, making even minor falls potentially result in fractures, which can significantly impact quality of life. Early detection and treatment can slow or halt the progression of osteoporosis, thereby lowering fracture risk. Consequently, the rising prevalence of osteoporosis heightens the demand for diagnosis, which in turn propels the growth of the osteoporosis treatment market. This condition is predominantly seen in women due to hormonal changes during menopause that affect bone density. Other contributing factors to osteoporosis risk in older adults include rheumatoid arthritis, a family history of the disease, and prolonged use of medications that weaken bones. According to the International Osteoporosis Foundation, among those with osteoporosis, 25% are women and 5% are men aged over 65.

Market Overview:Osteoporosis is a progressive condition that poses a high risk of fractures in men, postmenopausal women, and the elderly. Patients with osteoporosis are particularly vulnerable to fractures in the bones, hips, forearms, spine, and wrists. It is classified as a metabolic disorder that reduces bone mineral density, leading to fractures. Treatment options typically include bisphosphonates, hormone therapy, denosumab, and various nutritional supplements, along with lifestyle changes such as increased physical activity and a diet rich in calcium. Key factors driving the growth of the osteoporosis treatment market include rising healthcare expenditures on research and drug development, as well as growing awareness of available osteoporosis treatments.

Strategic Insights Market Driver: Rising Incidence of Osteoporosis and Lifestyle Changes Fuel Market Expansion

The global prevalence of osteoporosis is on the rise, primarily due to unhealthy lifestyles, poor nutrition, insufficient exercise, low calcium and vitamin D intake, and hormonal imbalances. The International Osteoporosis Foundation reports that osteoporosis leads to over 8.9 million fractures annually, equating to one osteoporotic fracture every three seconds, affecting approximately 200 million women worldwide. The increasing elderly population is another significant factor contributing to the growth of the osteoporosis treatment market. A study published in Labiotech, "Advancements in Osteoporosis Research," indicates that around 10 million Americans have osteoporosis, with approximately 44 million having low bone density, heightening their risk for the disease. The likelihood of developing osteoporosis escalates with age; adults aged 50 and older are at a heightened risk for fractures. In the US, three-quarters of adults aged 65 and older who suffer hip fractures are women, with an estimated 15% to 36% of these patients dying within a year. A growing focus on holistic health and wellness promotes regular health screenings, including bone density assessments. As individuals increasingly monitor their bone health, early diagnosis and intervention become crucial, further driving market growth. The osteoporosis treatment market is significantly bolstered by heightened awareness of bone health, which fuels demand for both preventive and therapeutic solutions.

Segmental Analysis:

The analysis of the osteoporosis treatment market has been conducted by examining the following segments: drug class, type, route of administration, and distribution channel.

In terms of drug class, the osteoporosis treatment market is divided into RANKL inhibitors, bisphosphonates, selective estrogen receptor modulators (SERMs), hormone therapies, and others. The RANKL segment accounted for the largest market share in 2023, while the hormone therapies segment is projected to experience the highest CAGR from 2023 to 2031. The bisphosphonates segment also holds a significant share in the osteoporosis treatment market. Bisphosphonates, including alendronate and zoledronic acid, are effective in inhibiting bone resorption, enhancing bone density, and reducing fracture risk. Their extensive clinical history, regulatory approvals, and availability in both oral and intravenous forms make them a preferred choice among healthcare providers. Additionally, their cost-effectiveness and broad insurance coverage contribute to their widespread use in osteoporosis treatment.

The market is categorized by type into primary osteoporosis and secondary osteoporosis. The primary osteoporosis segment held a larger share of the osteoporosis treatment market in 2023. Primary osteoporosis is associated with aging, leading to a gradual decline in bone renewal. A study published in the National Library of Medicine titled "Prevalence of Primary Osteoporosis and Low Bone Mass in Postmenopausal Women and Associated Risk Factors" indicates that 30% of women over 50 globally have osteoporosis, with 8% to 9% of annual bone fractures attributed to this condition. Furthermore, men and women aged 70 and older experience an imbalance between bone formation and loss, resulting in back pain, diminished quality of life, and difficulties in daily activities.

Regarding the route of administration, the osteoporosis treatment market is divided into oral and injectable forms. The injectable segment held the largest market share in 2023 and is expected to register the highest CAGR from 2023 to 2031. The dominance of the injectable segment can be attributed to its effectiveness and reliability as a drug delivery method. Administering treatment via injections allows for direct entry of the drug into the bloodstream, ensuring rapid and predictable absorption, which is crucial in osteoporosis treatment. Additionally, some osteoporosis medications are exclusively available in injectable form, further enhancing this segment's market share. With improved patient compliance for self-administered injections and ongoing advancements in drug delivery technologies, the injectable segment is well-positioned to maintain its strong market presence.

Regional Analysis:The osteoporosis treatment market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 8.26 billion in 2023 and is projected to reach US$ 11.26 billion by 2031, with an expected CAGR of 3.9% during 2023 to 2031. A significant factor driving market growth in this region is the large aging population, coupled with increased awareness of osteoporosis. Additionally, advanced healthcare infrastructure and comprehensive access to medical services facilitate timely diagnosis and treatment. The presence of major pharmaceutical companies and ongoing research and development efforts are also fostering the introduction of innovative therapies. Furthermore, favorable reimbursement policies and insurance coverage support patients seeking osteoporosis treatment, thereby promoting market growth in North America.

The Asia Pacific osteoporosis treatment market is anticipated to achieve the highest CAGR of 4.7%. This region, particularly countries like India and China, boasts a substantial pharmaceutical industry, with China serving as a manufacturing hub. The projected growth in this region is driven by a burgeoning middle class and improved access to healthcare. Moreover, advancements in healthcare infrastructure and the emerging pharmaceutical sector position the Asia Pacific as a key area for significant growth and development in the osteoporosis treatment market.

Osteoporosis Treatment Market Report Scope Key Player Analysis:Key players profiled in the osteoporosis treatment market report include Pfizer Inc., Amgen Inc., Cadila Pharmaceuticals, Eli Lilly and Company, Daiichi Sankyo Company, Limited, Teva Pharmaceuticals Inc., Asahi Kasei Corporation, Novartis AG, Chugai Pharmaceutical Co., Ltd., and Teijin Pharma Limited.

Recent Developments:

Companies in the osteoporosis treatment market are employing mergers and acquisitions as primary growth strategies. Recent developments in the market include:

In October 2021, Entera Bio, a prominent biotechnology firm, announced significant data from its mid-stage oral osteoporosis drug formulation study, advancing to Phase 3 registration.In August 2021, the Drug Controller General of India (DCGI) granted Marketing Authorization (MA) to Enzene Biosciences Ltd for its biosimilar drug Denosumab, indicated for osteoporosis treatment in adults.In January 2021, Theramex, a London-based pharmaceutical company, launched the osteoporosis drug Livogiva in Europe.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Osteoporosis Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Osteoporosis Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Osteoporosis Treatment Market - Global Market Analysis

  • 6.1 Osteoporosis Treatment - Global Market Overview
  • 6.2 Osteoporosis Treatment - Global Market and Forecast to 2031

7. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2021-2031

  • 7.1 Overview
  • 7.2 Rank Ligand (RANKL) Inhibitor
  • 7.3 Bisphosphonates
  • 7.4 Hormone
  • 7.5 Selective Estrogen Receptor Modulators (SERMs)
  • 7.6 Others

8. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Route of Administration, 2021-2031

  • 8.1 Overview
  • 8.2 Oral
  • 8.3 Injectable

9. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 9.1 Overview
  • 9.2 Primary Osteoporosis
  • 9.3 Secondary Osteoporosis

10. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Retail Pharmacies
  • 10.4 Online Pharmacies

11. Osteoporosis Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Osteoporosis Treatment Market Overview
    • 11.1.2 North America Osteoporosis Treatment Market Revenue and Forecasts to 2031
    • 11.1.3 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
    • 11.1.4 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Route of Administration
    • 11.1.5 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Type
    • 11.1.6 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.7 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Osteoporosis Treatment Market
        • 11.1.7.1.1 United States Osteoporosis Treatment Market, by Drug Type
        • 11.1.7.1.2 United States Osteoporosis Treatment Market, by Route of Administration
        • 11.1.7.1.3 United States Osteoporosis Treatment Market, by Type
        • 11.1.7.1.4 United States Osteoporosis Treatment Market, by Distribution Channel
      • 11.1.7.2 Canada Osteoporosis Treatment Market
        • 11.1.7.2.1 Canada Osteoporosis Treatment Market, by Drug Type
        • 11.1.7.2.2 Canada Osteoporosis Treatment Market, by Route of Administration
        • 11.1.7.2.3 Canada Osteoporosis Treatment Market, by Type
        • 11.1.7.2.4 Canada Osteoporosis Treatment Market, by Distribution Channel
      • 11.1.7.3 Mexico Osteoporosis Treatment Market
        • 11.1.7.3.1 Mexico Osteoporosis Treatment Market, by Drug Type
        • 11.1.7.3.2 Mexico Osteoporosis Treatment Market, by Route of Administration
        • 11.1.7.3.3 Mexico Osteoporosis Treatment Market, by Type
        • 11.1.7.3.4 Mexico Osteoporosis Treatment Market, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Osteoporosis Treatment Market - Key Company Profiles

  • 14.1 Teva Pharmaceutical Industries Ltd.
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc.
  • 14.3 Amgen Inc.
  • 14.4 Cadila Pharmaceuticals
  • 14.5 Daiichi Sankyo Company, Limited
  • 14.6 Chugai Pharmaceuticals Co. Ltd.
  • 14.7 Teijin Pharma Limited
  • 14.8 Novartis AG
  • 14.9 Eli Lily and Company
  • 14.10 Asahi Kasei Pharma Corporation

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud